Navigation Links
First observation of a human HAT, key proteins in numerous pathologies
Date:2/11/2014

The researcher Manuel Palacn, head of the Heterogenic and Multigenic Diseases lab at the Institute for Research in Biomedicine (IRB), in Barcelona, is among the world's experts in HATs (heteromeric amino acid transporters).

In humans, there are eight HAT molecules. These are associated, for example, with the following: rare diseases called aminoacidurias, such as lysinuric protein intolerance and cystinuria; the development of infections caused by the Kaposi sarcoma virus; various types of cancer; and relapse in cocaine use. HATs are, as the name implies, amino acid transporters, and they exert their action in the cell membrane. Because of their nature, they are extremely difficult to crystallize and consequently no structural data are available for these molecules at the atomic level. However, for rational drug design this information is imperative.

A study published this week in the journal Proceedings of the National Academy of Sciences USA (PNAS) has revealed the first structure of one of the eight HATs. Achieved through collaboration between biochemists at IRB, experts in electronic microscopy at the University of Bern, and computational biologists in the Joint IRB-BSC Programme, this breakthrough paves the way for further research into the functions of the other seven HATs and the resolution of their structures. Moreover, this study provides the first sufficiently detailed structural data to tackle their inhibition through drugs.

HATs and human pathologies

HAT proteins are formed by two parts or subunits, a light one which serves to transport amino acids and a heavier one that allows movement of the complex to the cell membrane, conferring it stability. In humans, six transporters form a complex with 4F2hc, while two do so with rBAT, thus totalling eight HATs. "They are mini machines that are inserted into the membrane and are in constant movement, engulfing amino acids from the extracellular spac
'/>"/>

Contact: Sònia Armengou
armengou@irbbarcelona.org
34-934-037-255
Institute for Research in Biomedicine (IRB Barcelona)
Source:Eurekalert  

Page: 1 2 3

Related medicine news :

1. Beaumont Health System first outside of Japan to test new atrial fibrillation technology
2. CONRAD wins USAID Science and Technology Pioneers Prize for development of first vaginal gel proven to reduce HIV
3. Maternal-fetal medicine professionals identify ways to reduce first cesarean
4. A scientific first: Physicists, physicians, engineers photograph radiation beams in the human body through the Cherenkov effect
5. NCCS and Clearbridge Biomedics open the regions first circulating tumor cell center
6. Dr Steven Shoshany to Become First NYC Chiropractor to Accept Bitcoin
7. A Priceless Resolution: Take That First Step Toward Financial Security
8. Dr. Kanani Announces Complimentary Consultations for First Time Patients
9. New NuGo Stronger: First Non-GMO High Protein Bar with rBGH-Free Whey Protein for Serious Athletes
10. PCG Kids Pediatric Care Group Voted in Top 20 Finalist to Win Philly's First Business Award From Firstrust Bank
11. Sarantos Releases First Music Video - "Not Where I Wanna Be"
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
First observation of a human HAT, key proteins in numerous pathologies
(Date:8/29/2014)... Astoria, New York, (PRWEB) August 29, 2014 ... a degenerative condition that damages the motor neurons in the ... and more of the nerve cells controlling movement are harmed, ... functions. Eventually this leads to death. , ALS is ... and 70, and as many as 30,000 Americans have the ...
(Date:8/29/2014)... Top10BestSEOHosting.com today compares many professional ... announces that Bluehost ( http://www.bluehost.com/track/seohosts ), Arvixe, and ... for webmasters who want to buy high quality ... at affordable rates. , Bluehost is also a ... its features is that Bluehost provides quality hosting ...
(Date:8/29/2014)... CA (PRWEB) August 29, 2014 According ... a lawsuit against Pfizer Inc., Greenstone LLC and Pfizer ... with congenital birth defects as a result of ... defect lawsuit was filed in St. Clair County Circuit ... to the lawsuit, the defendant companies allegedly concealed the ...
(Date:8/29/2014)... Visiting Nurse Association of Northern New ... delivering comfort and companionship to terminally-ill patients and their ... continues to grow and their needs expand, the VNA ... The next Hospice Training Program will be offered on ... P.M. at VNA’s headquarters, 175 South Street in Morristown. ...
(Date:8/29/2014)... The Winscribe Board of Directors today announced the ... from 1st September 2014. Allen previously held the position ... time of growth, there is no better person to ... Founder and Chairman of the Board. “Allen is a ... management experience gained in New Zealand, Europe and the ...
Breaking Medicine News(10 mins):Health News:Charity Event to Raise Awareness and Donations for the ALS Foundation 2Health News:Top10BestSEOHosting.com: Bluehost, Arvixe, and Hostgator Are the Best Windows Web Hosting from the USA in 2014 2Health News:The Law Office of Melinda J. Helbock A.P.C. Comments on Zoloft Birth Defect Lawsuit 2Health News:VNA Offers Rewarding Hospice Volunteer Opportunity 2Health News:VNA Offers Rewarding Hospice Volunteer Opportunity 3Health News:Winscribe Names Greg Allen as CEO 2
... Blue Cross and Blue Shield of Georgia (BCBSGA) ... reached agreement on a three-year contract, effective August ... members can continue to access Piedmont Healthcare as ... physicians, Piedmont Hospital in Atlanta, Piedmont Fayette Hospital ...
... North America,s largest annual interdisciplinary academic conference kicks off in ... Carleton University to present and debate research from across the ... will be held this Friday at 10:30 a.m. in the ... of what to expect. , Nathalie Des Rosiers, president of ...
... By combining the expertise of its ... (BEZ.L) has developed enhanced management liability coverage ... of healthcare organizations, including hospitals, long term ... is an adaptation of Beazley,s successful BeazleyOne ...
... calls to consider reducing the legal drinking age, a new University of ... births among young people. , ... Athens, Ga. (Vocus) May 21, 2009 ... new University of Georgia study finds that lower drinking ages ...
... May 21 For the second year in a ... to donate blood through the Red Cross by joining ... Red Cross Racing is a program designed to increase ... they donate. Participants of this program can get points for ...
... shows droplets rubbed into skin prevented infections , , THURSDAY, ... rubbed into the skin appear to protect against ear ... , If this approach proves effective in humans, it ... infections, the researchers noted. , Three groups of chinchillas ...
Cached Medicine News:Health News:Blue Cross and Blue Shield of Georgia and Piedmont Healthcare Announce Contract Renewal 2Health News:Thousands of Canada's best minds converge at Congress 2009 2Health News:Beazley's New Management Liability Coverage is Tailored to Unique Needs of Healthcare Organizations 2Health News:Beazley's New Management Liability Coverage is Tailored to Unique Needs of Healthcare Organizations 3Health News:Study: Lower Legal Drinking Age Increases Poor Birth Outcomes 2Health News:Study: Lower Legal Drinking Age Increases Poor Birth Outcomes 3Health News:NASCAR Fans Boost Blood Donations; The American Red Cross Joins 3M and Greg Biffle to Kick off Season Two 2Health News:NASCAR Fans Boost Blood Donations; The American Red Cross Joins 3M and Greg Biffle to Kick off Season Two 3Health News:Pediatric Ear Infection Vaccine Shows Promise 2
(Date:8/28/2014)... NEW YORK , Aug. 28, ... a new market research report is ... Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets ... Target High Unmet Need in Newly ... http://www.reportlinker.com/p02343492/Glioblastoma-Multiforme-Therapeutics-in-Asia-Pacific-Markets-to-2020---Novel-Therapeutic-Approaches-Target-High-Unmet-Need-in-Newly-Diagnosed-and-Recurrent-GBM.html ...
(Date:8/28/2014)... DIEGO , Aug. 28, 2014 Telik, ... development company that merged with MabVax Therapeutics, Inc. ... made significant progress related to the development of ... antibody was recovered using the Company,s internally developed ... the potential for multiple antibody based therapeutic and ...
(Date:8/28/2014)... Calif. , Aug. 28, 2014 Amgen ... of a Biologics License Application (BLA) to the U.S. ... for the treatment of high cholesterol. Evolocumab is an ... subtilisin/kexin type 9 (PCSK9), a protein that reduces the ... "bad" cholesterol, from the blood. 1 ­ ...
Breaking Medicine Technology:Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 2Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 3Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 4Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 5Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 6Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 7Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 8Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 9Telik Reports Progress Toward Multiple Early Stage Milestones in the Development of a Novel Antibody-based Therapeutic Agent for Gastrointestinal Cancers 2Telik Reports Progress Toward Multiple Early Stage Milestones in the Development of a Novel Antibody-based Therapeutic Agent for Gastrointestinal Cancers 3Telik Reports Progress Toward Multiple Early Stage Milestones in the Development of a Novel Antibody-based Therapeutic Agent for Gastrointestinal Cancers 4Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 2Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 3Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 4Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 5Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 6Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 7Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 8Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 9
... A surgeon at the St. Francis Heart Center ... to rebuild their own cardiovascular tissue. , , (Logo: ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20090708/DE43062LOGO-b ) ... Extracellular Matrix (ECM)(TM) to modify and repair cardiac structures, allowing ...
... Calif., July 7 Amgen (Nasdaq: AMGN ... trial evaluating denosumab versus Zometa(R) (zoledronic acid) in the ... breast cancer met its primary and secondary endpoints and ... demonstrated for both delaying the time to the first ...
Cached Medicine Technology:St. Francis Surgeon Uses Tissue Regeneration Technology to Rebuild Patients' Heart Structures 2St. Francis Surgeon Uses Tissue Regeneration Technology to Rebuild Patients' Heart Structures 3Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 2Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 3Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 4Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 5Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 6Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 7Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 8
The Medtronic CardioRhythm Marinr Catheter is intended for use in diagnostic electrophysiologic procedures. These catheters are designed for recording intracardiac electrograms and temporary pacing a...
... designed for use with our CARTO EP ... catheter houses a Biosense Webster sensor at ... time, exact location points from within the ... The NAVI-STAR electro-anatomical navigation catheter is used ...
... Tricuspid Mapping. Biosense Webster offers a complete ... in the atrium. The HALO XP 20-pole ... and mapping around the tricuspid annulus. The ... distal tip (on P15-FS/0 permit pacing in ...
... Webster is the source for a complete ... left-sided mapping - all with the quality, ... expect from the leader in catheter technology. ... specifically designed and constructed to help minimize ...
Medicine Products: